Assessing Response to Treatment in Non-Hodgkin's Lymphoma Patients Using 64Cu-DOTA-Rituximab PET/CT
| Status: | Withdrawn |
|---|---|
| Conditions: | Lymphoma |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | January 2012 |
| End Date: | December 2015 |
Rituximab is an antibody targeted against the CD20 antigen found primarily on B-cells.
Therefore, an imaging agent targeting CD20 expression may provide a more accurate evaluation
of extent of disease and response to therapy than the current standard of care, F-18 FDG
PET/CT.
The main purpose of the study is to investigate a new PET/CT imaging probe for detection and
follow up of lymphoma. Following are the 3 aims of the study: a) Phase I testing in lymphoma
patients of Cu-64 labelled Rituxan for defining normal tracer biodistribution, stability,
pharmacokinetics and radiation dosimetry; b) comparison of Cu-64 Rituxan and F-18 FDG PET/CT
in lymphoma patients; c) evaluation of changes in uptake of Cu-64 Rituxan in response to
rituximab-based treatment in CD20-positive B-cell NHL
Therefore, an imaging agent targeting CD20 expression may provide a more accurate evaluation
of extent of disease and response to therapy than the current standard of care, F-18 FDG
PET/CT.
The main purpose of the study is to investigate a new PET/CT imaging probe for detection and
follow up of lymphoma. Following are the 3 aims of the study: a) Phase I testing in lymphoma
patients of Cu-64 labelled Rituxan for defining normal tracer biodistribution, stability,
pharmacokinetics and radiation dosimetry; b) comparison of Cu-64 Rituxan and F-18 FDG PET/CT
in lymphoma patients; c) evaluation of changes in uptake of Cu-64 Rituxan in response to
rituximab-based treatment in CD20-positive B-cell NHL
Inclusion Criteria:
- Patients must have a diagnosis of CD20-positive B-cell NHL and a staging 18F FDG
PET/CT prior to the 64Cu-DOTA-Rituximab PET/CT
- Patients must understand and voluntarily sign an Informed Consent form after the
contents have been fully explained to them
- Patients must be scheduled for rituximab-based therapy
- Patients must be older than 18-year-old
Exclusion Criteria:
- Patients who cannot complete a PET/CT scan
- Pregnant women
- Patients participating in other research protocols will be excluded from this study
We found this trial at
1
site
Stanford University Cancer Institute The Stanford Cancer Institute (SCI) focuses the world-class expertise of more...
Click here to add this to my saved trials
